Clinical Trial Search

Phase 3 N=196 Clinical Study to Evaluate the Efficacy and Safety of VR506 Using a New Inhaler for the Treatment of Asthma

Asthma

Primary: Mean Prednisone/Prednisolone Dose for Analysis (PDA) at End of Study (Week 16) — 4.55; 4.31; 3.97 mg — p=0.772

Vectura Limited Results Apr 2020 0.0% serious AE View details

Phase 3 N=128 An Open Label Trial of ALD403 (Eptinezumab) in Chronic Migraine

Migraine Disorder

Primary: Number of Participants With Any Treatment Emergent Adverse Events (TEAEs) — 91 Participants

Alder Biopharmaceuticals, Inc. Results Apr 2020 3.9% serious AE View details

Phase 3 N=303 Erlotinib Prevention of Oral Cancer (EPOC)

Oral Cancer

Primary: Oral Cancer-free Survival in Participants Receiving Erlotinib as Compared With the Control Arm or Placebo Group. — 55; 18 Participants

M.D. Anderson Cancer Center Results Apr 2020 9.3% serious AE View details

Phase 3 N=205 A Randomized Trial to Compare Busulfan + Melphalan 140 mg/m2 With Melphalan 200 mg/m2 as Preparative Regimen for Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma

Myeloma

Primary: Progression-Free Survival (PFS) — 72; 50 Participants

M.D. Anderson Cancer Center Results Apr 2020 52.0% serious AE View details

Phase 3 N=816 Phase 3 Safety and Efficacy Study of ART-123 in Subjects With Severe Sepsis and Coagulopathy

Severe Sepsis · Coagulopathy

Primary: Number of Participants With 28-Day All-cause Mortality — 106; 119 Participants — p=0.318

Asahi Kasei Pharma America Corporation Results Apr 2020 51.0% serious AE View details

Phase 3 N=373 Clinical Study to Evaluate the Efficacy of VR506 Using a New Inhaler for the Treatment of Asthma

Asthma

Primary: Mean Change From Start of Treatment Baseline to End of Study (Week 12) for In-clinic Morning Pre-Dose Forced Expiratory Volume In 1 Second (FEV1) — 0.19; 0.32; 0.38…

Vectura Limited Results Apr 2020 0.5% serious AE View details

Phase 3 N=123 Cardiovascular Inflammation Reduction Trial - Inflammation Imaging Study

Vascular Inflammation · Atherosclerotic Cardiovascular Disease

Primary: Change in Arterial Inflammation — 0.03; 0.20 percent change

Icahn School of Medicine at Mount Sinai Results Apr 2020 0.0% serious AE View details

Phase 3 N=2,230 Evaluation of Long-Term Safety and Tolerability of ETC-1002 in High-Risk Patients With Hyperlipidemia and High CV Risk (CLEAR Harmony)

Hypercholesterolemia · Atherosclerotic Cardiovascular Diseases

Primary: Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) — 78.7; 78.5; 14.0; 14.5 percentage of participants

Esperion Therapeutics, Inc. Results Apr 2020 14.4% serious AE View details

Phase 3 N=186 Evaluation of Safety and Efficacy, Including Pharmacokinetics, of NNC 0129-0000-1003 When Administered for Treatment and Prophylaxis of Bleeding in Subjects With Haemophilia A

Congenital Bleeding Disorder · Haemophilia A

Primary: The Incidence Rate of FVIII-inhibitors ≥0.6 BU: After Approximately 19 Months — 0.006; 0 Inhibitor rate

Novo Nordisk A/S Results Apr 2020 13.6% serious AE View details

Phase 3 N=524 Rituximab and Combination Chemotherapy in Treating Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma

Large B Cell Lymphoma

Primary: Progression-Free Survival Rate at 2 and 5 Years — 78.9; 75.5; 68.0; 66.0 percentage of participants — p=0.6519

Alliance for Clinical Trials in Oncology Results Apr 2020 92.9% serious AE View details

Phase 3 N=66 Effects of Antidepressant Therapy on Brain Dopamine Transporter Activity in People With Major Depression

Depression

Primary: Change in Dopamine Transporter Binding

University of Pennsylvania Results Apr 2020 View details

Phase 3 N=242 A Study to Assess the Safety and Efficacy of Lacosamide Versus Placebo (a Pill Without Active Medication) in Patients With Idiopathic Generalised Epilepsy Who Are Already Taking Anti-epileptic Medications

Epilepsy

Primary: Time to the Second Primary Generalized Tonic Clonic (PGTC) Seizure During the 24-week Treatment Period From Visit 2 (Week 0) to Visit 10 (Week 24) — 76; 49 events…

UCB BIOSCIENCES, Inc. Results Apr 2020 3.5% serious AE View details

Phase 3 N=537 Imipenem/Relebactam/Cilastatin Versus Piperacillin/Tazobactam for Treatment of Participants With Bacterial Pneumonia (MK-7655A-014)

Bacterial Pneumonia

Primary: Percentage of Participants With All-cause Mortality (ACM) Through Day 28 in the Modified Intention-to-treat (MITT) Population — 15.9; 21.3 Percentage of participants…

Merck Sharp & Dohme LLC Results Apr 2020 29.3% serious AE View details

Phase 3 N=7 EZN-2279 in Patients With ADA-SCID

ADA-SCID · Adenosine Deaminase Deficiency · Severe Combined Immunodeficiency

Primary: Number of Patients Detoxified At Each Visit in EZN-2279 Treatment Period — 6; 6; 6; 5 Participants

Leadiant Biosciences, Inc. Results Apr 2020 28.6% serious AE View details

Phase 3 N=30 Effects of Cognitive Behavioral Therapy on Brain Serotonin Activity in People With Depression

Depression

Primary: Change in Serotonin Transporter Availability

University of Pennsylvania Results Apr 2020 View details